CA2128211A1 - A major histocompatibility complex class ii antigen in a vaccine against an immunodeficiency virus - Google Patents
A major histocompatibility complex class ii antigen in a vaccine against an immunodeficiency virusInfo
- Publication number
- CA2128211A1 CA2128211A1 CA002128211A CA2128211A CA2128211A1 CA 2128211 A1 CA2128211 A1 CA 2128211A1 CA 002128211 A CA002128211 A CA 002128211A CA 2128211 A CA2128211 A CA 2128211A CA 2128211 A1 CA2128211 A1 CA 2128211A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- cells
- virus
- animals
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 41
- 229960005486 vaccine Drugs 0.000 title claims abstract description 36
- 239000000427 antigen Substances 0.000 title claims abstract description 34
- 108091007433 antigens Proteins 0.000 title claims abstract description 34
- 102000036639 antigens Human genes 0.000 title claims abstract description 34
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 13
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims abstract description 13
- 230000007813 immunodeficiency Effects 0.000 title claims abstract description 13
- 102000043131 MHC class II family Human genes 0.000 title claims abstract description 11
- 108091054438 MHC class II family Proteins 0.000 title claims abstract description 11
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract description 8
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 7
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 4
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 3
- 108010010378 HLA-DP Antigens Proteins 0.000 claims abstract description 3
- 102000015789 HLA-DP Antigens Human genes 0.000 claims abstract description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims abstract 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims abstract 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract 2
- 241001465754 Metazoa Species 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 60
- 241000282553 Macaca Species 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 241000282567 Macaca fascicularis Species 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 101710091045 Envelope protein Proteins 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 102100021696 Syncytin-1 Human genes 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000726306 Irus Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 4
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100539892 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) USA1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700027479 Syntex adjuvant formulation Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929201023A GB9201023D0 (en) | 1992-01-17 | 1992-01-17 | Vaccines |
| GB9201023.0 | 1992-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2128211A1 true CA2128211A1 (en) | 1993-07-22 |
Family
ID=10708778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002128211A Abandoned CA2128211A1 (en) | 1992-01-17 | 1993-01-18 | A major histocompatibility complex class ii antigen in a vaccine against an immunodeficiency virus |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0623147A1 (de) |
| JP (1) | JPH07505613A (de) |
| AU (1) | AU3359693A (de) |
| CA (1) | CA2128211A1 (de) |
| GB (1) | GB9201023D0 (de) |
| WO (1) | WO1993014126A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1274592B (it) * | 1994-08-05 | 1997-07-18 | Angela Turiano | Composizione farmaceutica per la terapia tumorale contenente xenoantigeni |
| US6168787B1 (en) * | 1995-04-24 | 2001-01-02 | John Wayne Cancer Institute | Pluripotent vaccine against enveloped viruses |
| FR2735984B1 (fr) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic |
| WO1997036601A1 (en) * | 1996-04-03 | 1997-10-09 | Anergen, Inc. | Cyclic peptide vaccines for treatment and prevention of diabetes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2591227B1 (fr) * | 1985-12-06 | 1988-11-10 | Pasteur Institut | Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications |
-
1992
- 1992-01-17 GB GB929201023A patent/GB9201023D0/en active Pending
-
1993
- 1993-01-18 JP JP5512301A patent/JPH07505613A/ja active Pending
- 1993-01-18 WO PCT/GB1993/000102 patent/WO1993014126A1/en not_active Application Discontinuation
- 1993-01-18 AU AU33596/93A patent/AU3359693A/en not_active Abandoned
- 1993-01-18 EP EP93902402A patent/EP0623147A1/de not_active Withdrawn
- 1993-01-18 CA CA002128211A patent/CA2128211A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB9201023D0 (en) | 1992-03-11 |
| WO1993014126A1 (en) | 1993-07-22 |
| AU3359693A (en) | 1993-08-03 |
| JPH07505613A (ja) | 1995-06-22 |
| EP0623147A1 (de) | 1994-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Almond et al. | Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells | |
| Graham et al. | Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-blind trial | |
| EP1322665B1 (de) | Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen | |
| US20020151678A1 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
| AU734443C (en) | Vaccines | |
| US9737597B2 (en) | Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins | |
| Putkonen et al. | Long–term protection against SIV–induced disease in macaques vaccinated with a live attenuated HIV–2 vaccine | |
| CA2246359A1 (en) | Methods and compositions for protective and therapeutic genetic immunization | |
| SK18993A3 (en) | Vaccine and treatment method of hiv infection | |
| US8003113B2 (en) | DNA vaccine compositions and methods of use | |
| US9943593B2 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| EP2044950B1 (de) | Abgeschwächte Vif-DNA-Immunisierungskassetten für genetische Impfstoffe | |
| Temchura et al. | Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines | |
| Murphey-Corb et al. | Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys | |
| Mills et al. | Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28‐derived recombinant env and gag proteins | |
| Wagner et al. | Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques | |
| Gorse et al. | Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration | |
| CA2128211A1 (en) | A major histocompatibility complex class ii antigen in a vaccine against an immunodeficiency virus | |
| US20080085261A1 (en) | Vaccine Adjuvant | |
| Girard et al. | Progress in the development of HIV vaccines | |
| EP0328390B1 (de) | Peptidbehandlung von hartnäckigen Infektionskrankheiten | |
| Cole et al. | A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys | |
| HU et al. | Immune Responses to SIV mne Envelope Glycoproteins Protect Macaques from Homologous SIV Infection | |
| US20210177961A1 (en) | Feline leukemia virus vaccine | |
| Mills et al. | Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |